Last reviewed · How we verify
HRS-8427
HRS-8427 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.
HRS-8427 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells. Used for Cancer (specific indication under Phase 3 evaluation).
At a glance
| Generic name | HRS-8427 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Tyrosine kinase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HRS-8427 is an investigational small-molecule tyrosine kinase inhibitor developed by Jiangsu HengRui Medicine. While the precise molecular targets have not been widely disclosed in public literature, it is being evaluated in Phase 3 clinical trials for cancer indications. The drug is designed to inhibit aberrant kinase signaling that drives tumor growth and progression.
Approved indications
- Cancer (specific indication under Phase 3 evaluation)
Common side effects
Key clinical trials
- Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects (PHASE1)
- Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 (PHASE1)
- Pharmacokinetics and Safety of HRS-8427 in Healthy Volunteers and in Patients With Impaired Renal Function (PHASE1)
- Study on the Mass Balance of [14C]HRS-8427 for Injection in Healthy Chinese Subjects (PHASE1)
- A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia (PHASE2)
- A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis (PHASE3)
- A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-8427 CI brief — competitive landscape report
- HRS-8427 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI